Dr. Michael Woo heads Search and Evaluation in Immuno-Oncology at EMD Serono.  Michael has broad experiences in business development and drug development.  Prior to joining EMD Serono, Michael served in areas of increasing responsibility in Business Development & Licensing at Novartis Oncology, leading Due Diligence and actively participating in Search and Evaluation for oncology therapeutics.  Before joining Novartis, Michael was leading Due Diligence in the areas of Oncology, Immunology, Infectious Diseases, and Neuroscience in Roche Partnering.  Michael has been an active member of deal teams that have completed deals and strategic partnerships in Oncology and Immuno-Oncology.  Michael has also served on global program teams responsible for the development of small molecules and biologics in Oncology from Phase 1 through Regulatory filing at Bristol-Myers Squibb and at Roche.
Michael received a B.Sc.Phm. from the University of Toronto, an M.S.C.I. from Vanderbilt University, an M.B.A from New York University Stern School of Business, and a Doctor of Pharmacy from Wayne State University.  Michael completed his residency at M.D. Anderson Cancer Center and post-doctoral fellowships at St. Jude Children’s Research Hospital.
Michael is a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).